HTB

PRO-542 shows efficacy in trial

Polly Clayden, HIV i-Base

A report in the July issue of the Journal of Infected Diseases of a phase 1 study of PRO 542 – a recombinant antibody-like fusion protein that binds to and neutralises HIV-1 isolates, showed significant viral load reduction, good tolerability and no dose limiting toxicities, in HIV-infected adults.

Subjects were treated with a single intravenous infusion of PRO 542 at doses of 0.2-10 mg/kg. The drug was well tolerated, and the AUC and peak serum concentrations increased linearly with the dose, as did reduction in HIV-1 RNA. No patient developed antibodies to PRO 542.

Sustained antiviral effect may be achieved with dosing of PRO 542. This novel agent deserves further investigation.

Reference:

Single dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. Jacobson et al. J of Infect Dis 2000 Jul; 182(1):326-9

Links to other websites are current at date of posting but not maintained.